Sanofi Consumer Healthcare India Limited
3,262.80
INR
-94.20
(-2.81%)
ISIN
INE0UOS01011
Return %
Stock
S&P 500
1Y
-30.75
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Himanshu Bakshi
- Full Time Employees
- 597
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Unit 1104, 11th Floor Mumbai MA India 400079
- IPO Date
- Sep 13, 2024
- Website
- sanofi.in
- Similar Companies
- Business
- Sanofi Consumer Healthcare India Ltd. (SANOFICONR.NS) operates as the Indian subsidiary of Sanofi, focusing on the development, manufacturing, marketing, and distribution of consumer healthcare products including over-the-counter medicines, vitamins, minerals, supplements, and personal care items such as allergy remedies (e.g., Allegra), pain relief (e.g., Combiflam), digestive health solutions (e.g., Enterogermina), cough and cold treatments (e.g., Strepsils), skin care (e.g., Cetaphil), and women's health products (e.g., Combipatch). The company serves retail consumers, pharmacies, and healthcare professionals across India, with a presence in urban and rural markets through an extensive distribution network. Founded as part of Sanofi's global consumer healthcare division (established in 2019 following the spin-off from Sanofi proper), it is headquartered in Mumbai, India, and operates nationwide with manufacturing facilities supporting local production. In recent developments within the last 1-2 years, Sanofi Consumer Healthcare has expanded its portfolio through new product launches tailored to Indian consumers, including enhanced formulations in respiratory health and immunity boosters amid post-pandemic demand; it has also strengthened strategic partnerships with local distributors and e-commerce platforms like Amazon India and Flipkart to boost accessibility. The parent Sanofi group announced the sale of its India consumer healthcare business to Nova Nordisk in early 2025, marking a significant divestiture to refocus on pharmaceuticals, though operational continuity persists under transition; additionally, Sanofi introduced sustainability initiatives in packaging and supply chain for its Indian operations in 2024. These changes align with broader segment shifts in the consumer healthcare industry, emphasizing digital sales channels and localized innovation.